Drugs / TJ107
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04001075 | Feb 2019 → Jun 2021 | high grade malignant neoplasm | TJ Biopharma Co., Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05145907 | Dec 2021 → Jun 2024 | head and neck squamous cell carcinoma, triple-negative breast carcinoma | TJ Biopharma Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT04600817 | Dec 2020 → Dec 2024 | glioblastoma | TJ Biopharma Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TJ107 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04001075 ↗ |
| Route | Intramuscular | “TJ107 injection:1200ug/Kg, Q12W, IM” NCT05145907 ↗ |